Sugi Predict

Sugi Predict / Compounds / SCHEMBL15437795

SCHEMBL15437795

SCHEMBL15437795

O=C(CNc1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.64
▸ AGTR1 P30556 5/20 0.64
▸ RAB9A P51151 5/20 0.64
▸ SMN1; SMN2 Q16637 4/20 0.64
▸ NPC1 O15118 4/20 0.64
▸ HPGD P15428 4/20 0.64
▸ MAPT P10636 6/20 0.63
▸ GAA P10253 2/20 0.63
▸ KMT2A Q03164 7/20 0.63
▸ AKR1C3 P42330 1/20 0.58
▸ MEN1 O00255 6/20 0.55
▸ PTGS2 P35354 1/20 0.53
▸ KDM4E B2RXH2 2/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ CES1 P23141 2/20 0.50
▸ ALOX15 P16050 2/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ CES2 O00748 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6203064 0.91 ALDH1A1 (0.56) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL593746 0.87 AKR1C3 (0.73) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL19707256 0.85 ERCC5 (0.55) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL19707920 0.83 KMT2A (0.50) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL5786954 0.82 RAB9A (0.64) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL28365324 0.82 ALDH1A1 (0.64) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL19707317 0.82 AGTR1 (0.48) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL8805616 0.82 ALDH1A1 (0.64) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL19707558 0.82 RAB9A (0.69) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1
SCHEMBL19707725 0.81 MAPT (0.76) ALDH1A1AGTR1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834383-B2 Energetic feedstock for additive manufacturing LYNNTECH, INC. (US) 2023-12-05 — — US claimed
US-20210276931-A1 Energetic Feedstock for Additive Manufacturing LYNNTECH, INC. 2021-09-09 — — US claimed
US-11834383-B2 Energetic feedstock for additive manufacturing LYNNTECH, INC. (US) 2023-12-05 — — US disclosed
CN-114890908-B Gamma-trifluoromethyl amino acid derivative and preparation method thereof 华中科技大学 2023-04-21 — — CN disclosed
CN-114890908-A Gamma-position trifluoromethyl amino acid derivative and preparation method thereof 华中科技大学 2022-08-12 — — CN disclosed
US-20210276931-A1 Energetic Feedstock for Additive Manufacturing LYNNTECH, INC. 2021-09-09 — — US disclosed
CN-110818639-B Synthesis method of N-imido imidazole compound 东华理工大学 2021-03-02 — — CN disclosed
CN-110818639-A Synthesis method of N-imido imidazole compound 东华理工大学 2020-02-21 — — CN disclosed
US-20190134005-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARM INC (US) 2019-05-09 — — US disclosed
WO-2017214505-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2017-12-14 — — WO disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof SOST, MYD88, MSR1 ALDH1A1 3334/4885AGTR1 2827/4885RAB9A 423/4885
US-20190134005-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE UGCG, MAN2B1, GBA1 ALDH1A1 2406/4885AGTR1 4214/4885RAB9A 2174/4885
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof SOST, MYD88, MSR1 ALDH1A1 2526/4885AGTR1 2724/4885RAB9A 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.